CONMED Corporation is classed by the SEC under Electromedical & Electrotherapeutic Apparatus (industry code 3845), based in Largo, FL. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.4 billion and a profit of $47 million (its filed statements).
Product businessElectromedical & Electrotherapeutic ApparatusLargo, FLfilings since 19959 of 9 filed
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3845, Electromedical & Electrotherapeutic Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.2 out of ten, 9 of 9 metrics filed: past 5.7 out of ten, present 5.6 out of ten, future 4.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 5.0 out of ten. 1 warning event since 2017; the latest 2020-01-29. 50th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.8 out of ten. +6.8% a year over 10 filed years; profitable in 9 of 10. 57th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 6.8 out of ten. Share count grew 1.2% a year. 16% of cash flow returned. Insiders: 2 sales, 0 purchases. 68th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 5.7 out of ten. ROE 5%: 5¢ of profit per shareholder dollar. Leverage 56%: owes 56¢ per asset dollar. 57th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 6.8 out of ten. top 32% of 24 in its family; net margin 3.4%. 68th percentile among 24 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 3.5 out of ten. bottom 35% of 19 in its family for leadership; chief executive since 2025. 35th percentile among 19 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 3.5 out of ten. bottom 35% of 23 in its family for room to expand. 35th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 4.6 out of ten. bottom 46% of 25 in its family for growth drivers. 46th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 4.5 out of ten. bottom 45% of 20 in its family for expectations against reality. 45th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-17 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-29 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-29 (on EDGAR). Newest filing: Form 4, 2026-09-10. Filings on record since 1995. Read from EDGAR 2026-10-12.
Who runs it
Beyer, Pat (President & CEO); Gallagher, John E (Executive Vice President & CFO); Ferrell, John D. (Executive Vice President - HR); Garner, Todd W. (Executive Vice President & CFO); Glaze, Richard (Chief Information Officer); Lockwood, Kimberly (Interim Corp Controller & PAO); Foust, Hollie K (General Counsel & Corp Sec); Lalomia, Brent (Executive VP RA, QA); Schabacker, Matthew (VP GM Advanced Surgical); Shagory, Peter K (EVP, STRAT & CORP DEVT); and 10 more. 20 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.